{
    "clinical_study": {
        "@rank": "132798", 
        "acronym": "POUDER", 
        "arm_group": [
            {
                "arm_group_label": "Verum, broccoli sprout grain", 
                "arm_group_type": "Experimental", 
                "description": "Active sulforaphane distributed in capsules each containing broccoli sprout grain"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Inactive substances (methylcellulose) with identical capsule and portion distribution"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of the POUDER trial is to determine the feasibility of a randomized controlled\n      trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and\n      quercetin in patients with advanced pancreatic ductal adenocarcinoma that receive palliative\n      chemotherapy."
        }, 
        "brief_title": "Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Ductal Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms", 
                "Carcinoma, Ductal, Breast"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be randomly classified into two groups - verum and placebo. The patients in\n      the experimental arm will receive capsules with broccoli sprout grain containing a total of\n      90mg sulforaphane active substance per day over one year as nutrition supplement whereas\n      patients assigned to the placebo group will receive inactive substance (methylcellulose)\n      with identical capsule and portion distribution."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced, surgically non-treatable pancreatic ductal adenocarcinoma (surgical\n             exploration, intraoperative biopsy but also palliative bypass interventions\n             (bileodigestive anastomosis and/or gastroenterostomy because of preoperative\n             cholestasis or impaired gastric emptying due to tumor-mass effect)\n\n          -  Intact gastric emptying\n\n          -  Written informed consent\n\n          -  Patients \u226518 years of age\n\n          -  Palliative chemotherapy\n\n        Exclusion Criteria:\n\n          -  Intolerance to broccoli or its ingredients\n\n          -  Impaired mental status or language problems / barriers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879878", 
            "org_study_id": "POUDER", 
            "secondary_id": "U1111-1144-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Verum, broccoli sprout grain", 
                "description": "Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.", 
                "intervention_name": "Verum, broccoli sprout grain", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "glucoraphanin"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.", 
                "intervention_name": "placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sulforafan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pancreatic adenocarcinoma", 
            "broccoli sprouts", 
            "sulforaphane", 
            "palliative chemotherapy", 
            "cancer stem cells"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "contact": {
                "email": "vladimir.lozanovski@med.uni-heidelberg.de", 
                "last_name": "Vladimir J. Lozanovski, M.D.", 
                "phone": "+49 6221 5636439"
            }, 
            "facility": {
                "address": {
                    "city": "Heidelberg", 
                    "country": "Germany", 
                    "zip": "69120"
                }, 
                "name": "Dept. of General and Transplant Surgery, University Hospital of Heidelberg, Germany"
            }, 
            "investigator": {
                "last_name": "Vladimir J. Lozanovski, M.D.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]", 
        "other_outcome": {
            "description": "Urine analysis as marker of substance systemic bioavailability (conversion of the precursor glucoraphanin to the active drug substance sulforaphane). Urine analysis serves as control of the regular intake of the test substance as well.", 
            "measure": "Substance bioavailability", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "overall_contact": {
            "email": "peter.schemmer@med.uni-heidelberg.de", 
            "last_name": "Peter Schemmer, Prof. Dr. med.", 
            "phone": "+49 6221 566205"
        }, 
        "overall_contact_backup": {
            "email": "vladimir.lozanovski@med.uni-heidelberg.de", 
            "last_name": "Vladimir J. Lozanovski, M.D.", 
            "phone": "+49 6221 5636439"
        }, 
        "overall_official": [
            {
                "affiliation": "Heidelberg University", 
                "last_name": "Peter Schemmer, Prof. Dr. med.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Heidelberg University", 
                "last_name": "Ingrid Herr, Prof. Dr.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Main objective is to test the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced, surgically non-resectable pancreatic ductal adenocarcinoma treated with palliative chemotherapy", 
            "measure": "Feasibility of a randomized controlled trial", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879878"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Heidelberg University", 
            "investigator_full_name": "Peter Schemmer", 
            "investigator_title": "Prof. Dr. med. Peter Schemmer, MBA", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Disease status (cancer progress or regress): CT-imaging staging (if available) and serum tumor markers (CEA and CA-19-9) peaks as additional parameters that provide insight into disease status.", 
            "measure": "Disease status (imaging and tumor markers)", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "source": "Heidelberg University", 
        "sponsors": {
            "collaborator": {
                "agency": "German Cancer Research Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Heidelberg University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}